Tag Archive for: Medicxi

Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology

/in

ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata Significant progress made in advancing the Alys pipeline following $100m seed financing from Medicxi Boston, Massachusetts and Lausanne, Switzerland, 4th February 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) […]

Read more

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025

/in

David Epstein, formerly CEO of Seagen, joins as Chair & Chief Executive Officer Mehdi Shahidi, previously SVP and Chief Medical Officer at Boehringer Ingelheim, joins as Head of Development & Chief Medical Officer James Sabry, ex-Head of Pharma Partnering at Roche, joins the Board as Vice-Chair [28 October 2024]: [London, UK/ Boston, US]: Ottimo Pharma, […]

Read more

Medicxi Announces $40m investment in D3 Bio

/in

Investment will support development of a differentiated pipeline in oncology Most advanced asset is D3S-001 with potential to be a best-in-class KRAS G12C inhibitor Data on lead asset D3S-001 to be presented at AACR on 8 April 2024  8 April 2024, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces an investment of […]

Read more

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

/in

Co-founded by world leading dermatology experts and Medicxi Merger of six asset-centric companies to form a new R&D-centric multi-platform pipeline in immuno-dermatology to harness cutting edge-science and technologies Vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet need Boston, Massachusetts and Geneva, Switzerland, 12th February 2024 – Alys Pharmaceuticals, Inc. […]

Read more

Medicxi Announces $400m Medicxi IV

/in

Fund to focus on its pioneering ‘asset-centric’ investment model, backing visionary biopharma entrepreneurs and drug hunters along the full drug development spectrum  27 July 2023, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces its $400 million Medicxi IV fund. The new fund will continue to support drug hunters with clear product […]

Read more